Cargando…
In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart
IgE antibodies elicit powerful immune responses, recruiting effector cells to tumors more efficiently and with greater cytotoxicity than IgG antibodies. Consequently, IgE antibodies are a promising alternative to conventional IgG-based therapies in oncology (AllergoOncology). As the pharmacokinetics...
Autores principales: | Man, Francis, Koers, Alexander, Karagiannis, Panagiotis, Josephs, Debra H., Bax, Heather J., Gilbert, Amy E., Dodev, Tihomir S., Mele, Silvia, Chiarruttini, Giulia, Crescioli, Silvia, Chauhan, Jitesh, Blower, Julia E., Cooper, Margaret S., Spicer, James, Karagiannis, Sophia N., Blower, Philip J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425638/ https://www.ncbi.nlm.nih.gov/pubmed/34513315 http://dx.doi.org/10.1080/2162402X.2021.1966970 |
Ejemplares similares
-
Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments
por: McCraw, Alex J., et al.
Publicado: (2021) -
An immunologically relevant rodent model demonstrates safety of therapy using a tumour‐specific IgE
por: Josephs, D. H., et al.
Publicado: (2018) -
IgE Antibodies against Cancer: Efficacy and Safety
por: Chauhan, Jitesh, et al.
Publicado: (2020) -
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
por: Chauhan, Jitesh, et al.
Publicado: (2023) -
In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model
por: Williams, Iwan P., et al.
Publicado: (2019)